| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 20 | 2025 | 926 | 4.810 |
Why?
|
| Percutaneous Coronary Intervention | 12 | 2026 | 222 | 4.120 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2026 | 788 | 3.250 |
Why?
|
| Atrial Fibrillation | 17 | 2025 | 854 | 3.200 |
Why?
|
| Cardiovascular Diseases | 13 | 2025 | 848 | 2.550 |
Why?
|
| Stroke | 15 | 2025 | 1196 | 2.520 |
Why?
|
| Coronary Artery Disease | 6 | 2025 | 320 | 2.480 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2023 | 270 | 2.260 |
Why?
|
| Pharmacovigilance | 4 | 2024 | 15 | 2.100 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 915 | 2.080 |
Why?
|
| Acute Coronary Syndrome | 3 | 2024 | 253 | 1.930 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2026 | 33 | 1.900 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2025 | 706 | 1.720 |
Why?
|
| ST Elevation Myocardial Infarction | 6 | 2025 | 96 | 1.660 |
Why?
|
| Humans | 106 | 2026 | 64238 | 1.650 |
Why?
|
| Catheter Ablation | 6 | 2025 | 155 | 1.630 |
Why?
|
| Coronary Artery Bypass | 4 | 2025 | 297 | 1.610 |
Why?
|
| Kidney Diseases | 3 | 2025 | 180 | 1.610 |
Why?
|
| Endovascular Procedures | 3 | 2025 | 607 | 1.600 |
Why?
|
| Heart Arrest | 4 | 2023 | 177 | 1.570 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2025 | 147 | 1.470 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2024 | 112 | 1.390 |
Why?
|
| Treatment Outcome | 29 | 2026 | 5691 | 1.390 |
Why?
|
| Angioedema | 2 | 2021 | 10 | 1.360 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2024 | 48 | 1.280 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 130 | 1.240 |
Why?
|
| Hypoglycemic Agents | 5 | 2025 | 221 | 1.210 |
Why?
|
| Risk Factors | 24 | 2025 | 5339 | 1.180 |
Why?
|
| Postoperative Complications | 3 | 2025 | 1294 | 1.170 |
Why?
|
| Aortic Valve Stenosis | 4 | 2024 | 190 | 1.150 |
Why?
|
| Aged | 35 | 2026 | 14648 | 1.090 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2023 | 233 | 1.060 |
Why?
|
| United States | 29 | 2025 | 7923 | 1.060 |
Why?
|
| Kidney Failure, Chronic | 3 | 2023 | 205 | 1.050 |
Why?
|
| Antihypertensive Agents | 2 | 2025 | 172 | 1.010 |
Why?
|
| Hospitalization | 19 | 2025 | 1368 | 1.000 |
Why?
|
| Hospital Mortality | 15 | 2025 | 870 | 0.960 |
Why?
|
| Conservative Treatment | 1 | 2026 | 18 | 0.950 |
Why?
|
| Stroke Volume | 7 | 2024 | 330 | 0.950 |
Why?
|
| Cardiovascular Agents | 3 | 2023 | 104 | 0.940 |
Why?
|
| Denervation | 1 | 2025 | 19 | 0.920 |
Why?
|
| Retrospective Studies | 24 | 2026 | 6726 | 0.910 |
Why?
|
| Heart-Assist Devices | 6 | 2025 | 149 | 0.900 |
Why?
|
| Male | 39 | 2026 | 30294 | 0.890 |
Why?
|
| Heart Transplantation | 3 | 2024 | 176 | 0.880 |
Why?
|
| Obesity | 4 | 2025 | 1247 | 0.870 |
Why?
|
| Alopecia | 1 | 2024 | 27 | 0.860 |
Why?
|
| Female | 41 | 2026 | 33350 | 0.860 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2025 | 103 | 0.860 |
Why?
|
| Databases, Factual | 8 | 2025 | 856 | 0.860 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2024 | 3 | 0.850 |
Why?
|
| Bayes Theorem | 1 | 2024 | 123 | 0.840 |
Why?
|
| Warfarin | 3 | 2023 | 122 | 0.840 |
Why?
|
| Coronary Occlusion | 1 | 2024 | 7 | 0.840 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 91 | 0.830 |
Why?
|
| Anticoagulants | 5 | 2023 | 511 | 0.830 |
Why?
|
| Myocardial Revascularization | 1 | 2024 | 76 | 0.820 |
Why?
|
| Length of Stay | 10 | 2025 | 818 | 0.810 |
Why?
|
| Amiodarone | 1 | 2023 | 22 | 0.810 |
Why?
|
| Recovery of Function | 2 | 2025 | 285 | 0.810 |
Why?
|
| Health Care Costs | 2 | 2022 | 215 | 0.800 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2023 | 14 | 0.800 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 16 | 0.770 |
Why?
|
| Defibrillators, Implantable | 3 | 2022 | 267 | 0.770 |
Why?
|
| Renal Dialysis | 2 | 2023 | 195 | 0.770 |
Why?
|
| Adult | 30 | 2026 | 17116 | 0.760 |
Why?
|
| Suicide | 1 | 2024 | 134 | 0.760 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 153 | 0.760 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2023 | 56 | 0.750 |
Why?
|
| Neoplasms | 9 | 2025 | 1392 | 0.750 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 63 | 0.750 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 95 | 0.740 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 66 | 0.730 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 94 | 0.730 |
Why?
|
| Mortality, Premature | 1 | 2021 | 7 | 0.730 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 181 | 0.720 |
Why?
|
| Thrombectomy | 1 | 2024 | 242 | 0.720 |
Why?
|
| Inpatients | 9 | 2024 | 303 | 0.720 |
Why?
|
| Middle Aged | 29 | 2026 | 17898 | 0.710 |
Why?
|
| Hyperkalemia | 1 | 2021 | 20 | 0.690 |
Why?
|
| Medicare | 2 | 2023 | 611 | 0.690 |
Why?
|
| Hypotension | 1 | 2021 | 50 | 0.670 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 160 | 0.670 |
Why?
|
| Shock, Cardiogenic | 4 | 2025 | 104 | 0.660 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 131 | 0.650 |
Why?
|
| Cardiovascular System | 1 | 2020 | 40 | 0.640 |
Why?
|
| Dementia | 1 | 2022 | 263 | 0.580 |
Why?
|
| Secondary Prevention | 1 | 2019 | 164 | 0.580 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 5520 | 0.570 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 774 | 0.550 |
Why?
|
| Young Adult | 10 | 2025 | 4776 | 0.510 |
Why?
|
| Atrial Appendage | 3 | 2022 | 38 | 0.510 |
Why?
|
| Cardiotoxicity | 4 | 2025 | 16 | 0.500 |
Why?
|
| Time Factors | 8 | 2025 | 3724 | 0.500 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2024 | 176 | 0.490 |
Why?
|
| Brain Ischemia | 1 | 2019 | 421 | 0.460 |
Why?
|
| Water Pollutants, Chemical | 2 | 2025 | 43 | 0.440 |
Why?
|
| Adolescent | 9 | 2025 | 6304 | 0.410 |
Why?
|
| Drug Combinations | 3 | 2023 | 168 | 0.380 |
Why?
|
| Embolism, Paradoxical | 1 | 2012 | 14 | 0.370 |
Why?
|
| Pandemics | 5 | 2023 | 676 | 0.370 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 13 | 0.370 |
Why?
|
| Myocarditis | 3 | 2024 | 70 | 0.370 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 95 | 0.360 |
Why?
|
| Hospitals | 6 | 2024 | 390 | 0.350 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 97 | 0.350 |
Why?
|
| Aminobutyrates | 2 | 2021 | 9 | 0.340 |
Why?
|
| Valsartan | 2 | 2021 | 12 | 0.340 |
Why?
|
| Tetrazoles | 2 | 2021 | 22 | 0.340 |
Why?
|
| Biphenyl Compounds | 2 | 2021 | 33 | 0.340 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 65 | 0.330 |
Why?
|
| Mortality | 3 | 2025 | 161 | 0.310 |
Why?
|
| Aortic Valve | 4 | 2024 | 190 | 0.310 |
Why?
|
| Risk Assessment | 6 | 2025 | 2046 | 0.300 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 142 | 0.300 |
Why?
|
| Atherosclerosis | 2 | 2021 | 156 | 0.300 |
Why?
|
| Ritonavir | 3 | 2023 | 19 | 0.300 |
Why?
|
| Hypertension | 2 | 2024 | 593 | 0.300 |
Why?
|
| Prevalence | 4 | 2025 | 1407 | 0.290 |
Why?
|
| Hemorrhage | 3 | 2024 | 274 | 0.270 |
Why?
|
| Coronary Angiography | 3 | 2023 | 209 | 0.250 |
Why?
|
| Propensity Score | 2 | 2024 | 167 | 0.250 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 63 | 0.240 |
Why?
|
| Child | 3 | 2024 | 4583 | 0.230 |
Why?
|
| Blood Pressure | 2 | 2025 | 517 | 0.230 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2025 | 6 | 0.230 |
Why?
|
| Seawater | 1 | 2025 | 12 | 0.230 |
Why?
|
| Femoral Artery | 2 | 2023 | 99 | 0.230 |
Why?
|
| Incretins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Mitral Valve | 2 | 2023 | 127 | 0.230 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 271 | 0.230 |
Why?
|
| Diabetes Mellitus | 2 | 2025 | 541 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 1 | 2026 | 97 | 0.220 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 13 | 0.220 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2024 | 22 | 0.220 |
Why?
|
| Diabetic Retinopathy | 1 | 2025 | 51 | 0.220 |
Why?
|
| Canagliflozin | 1 | 2024 | 6 | 0.220 |
Why?
|
| Glucosides | 1 | 2024 | 13 | 0.210 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 35 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2026 | 495 | 0.210 |
Why?
|
| Perioperative Care | 1 | 2025 | 86 | 0.210 |
Why?
|
| Vascular Diseases | 1 | 2024 | 82 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 77 | 0.200 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 107 | 0.200 |
Why?
|
| Furosemide | 1 | 2023 | 20 | 0.200 |
Why?
|
| Ibuprofen | 1 | 2023 | 17 | 0.200 |
Why?
|
| Benzhydryl Compounds | 1 | 2024 | 61 | 0.200 |
Why?
|
| Indomethacin | 1 | 2023 | 22 | 0.200 |
Why?
|
| Watchful Waiting | 1 | 2023 | 32 | 0.200 |
Why?
|
| Factor Xa Inhibitors | 1 | 2023 | 37 | 0.200 |
Why?
|
| Infant, Low Birth Weight | 1 | 2023 | 60 | 0.200 |
Why?
|
| Pyridones | 1 | 2023 | 42 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2025 | 220 | 0.200 |
Why?
|
| Benzoxazoles | 1 | 2023 | 7 | 0.200 |
Why?
|
| Health Status Disparities | 1 | 2024 | 144 | 0.200 |
Why?
|
| Prealbumin | 1 | 2023 | 19 | 0.200 |
Why?
|
| Popliteal Artery | 1 | 2023 | 24 | 0.200 |
Why?
|
| Rural Population | 2 | 2022 | 212 | 0.200 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 12 | 0.200 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 115 | 0.200 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 14 | 0.190 |
Why?
|
| Adenosine Diphosphate | 1 | 2023 | 44 | 0.190 |
Why?
|
| Catheterization, Peripheral | 1 | 2023 | 49 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2023 | 87 | 0.190 |
Why?
|
| Disability Evaluation | 1 | 2024 | 218 | 0.190 |
Why?
|
| Vascular Patency | 1 | 2023 | 134 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 145 | 0.190 |
Why?
|
| Patient Readmission | 2 | 2024 | 432 | 0.190 |
Why?
|
| Climate Change | 1 | 2022 | 25 | 0.190 |
Why?
|
| Paclitaxel | 1 | 2023 | 103 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2025 | 265 | 0.190 |
Why?
|
| Administration, Oral | 1 | 2023 | 374 | 0.190 |
Why?
|
| Reoperation | 1 | 2023 | 291 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2024 | 1375 | 0.190 |
Why?
|
| Overweight | 1 | 2024 | 252 | 0.190 |
Why?
|
| Regression Analysis | 1 | 2023 | 498 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 467 | 0.180 |
Why?
|
| Ultrasonography, Interventional | 1 | 2023 | 116 | 0.180 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 142 | 0.180 |
Why?
|
| Sex Characteristics | 1 | 2023 | 202 | 0.180 |
Why?
|
| Arthritis, Psoriatic | 1 | 2022 | 32 | 0.180 |
Why?
|
| Algorithms | 2 | 2024 | 1028 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2022 | 362 | 0.180 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 117 | 0.180 |
Why?
|
| Infant, Premature | 1 | 2023 | 184 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 460 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 215 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1272 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 46 | 0.170 |
Why?
|
| Giant Cells | 1 | 2021 | 15 | 0.170 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 12 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 158 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 176 | 0.170 |
Why?
|
| Population Surveillance | 1 | 2022 | 209 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 421 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2024 | 756 | 0.170 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 68 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 143 | 0.160 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 17 | 0.160 |
Why?
|
| Cardiology | 1 | 2022 | 170 | 0.160 |
Why?
|
| Anemia | 1 | 2021 | 128 | 0.160 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 71 | 0.160 |
Why?
|
| Cardiac Catheterization | 4 | 2022 | 292 | 0.150 |
Why?
|
| Asthma | 1 | 2023 | 471 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2023 | 3315 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 437 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 666 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 183 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 698 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 1211 | 0.110 |
Why?
|
| Comorbidity | 3 | 2023 | 1118 | 0.110 |
Why?
|
| Quality of Life | 1 | 2022 | 1257 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2026 | 2604 | 0.100 |
Why?
|
| Coronary Disease | 2 | 2012 | 246 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2616 | 0.090 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2012 | 51 | 0.090 |
Why?
|
| Sex Factors | 2 | 2024 | 979 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 46 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2026 | 2478 | 0.080 |
Why?
|
| Pregnancy | 2 | 2024 | 2370 | 0.060 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 14 | 0.060 |
Why?
|
| Datasets as Topic | 1 | 2025 | 28 | 0.060 |
Why?
|
| Mobility Limitation | 1 | 2025 | 49 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 22 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 26 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2024 | 53 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2024 | 21 | 0.050 |
Why?
|
| Lactams | 1 | 2023 | 24 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Proline | 1 | 2023 | 49 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2025 | 249 | 0.050 |
Why?
|
| Spasm | 1 | 2023 | 10 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2023 | 12 | 0.050 |
Why?
|
| Heart Rate | 1 | 2025 | 327 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2023 | 12 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 102 | 0.050 |
Why?
|
| Nitriles | 1 | 2023 | 79 | 0.050 |
Why?
|
| Leucine | 1 | 2023 | 67 | 0.050 |
Why?
|
| Diuretics | 1 | 2023 | 59 | 0.050 |
Why?
|
| Recurrence | 1 | 2025 | 650 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 38 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2023 | 106 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 195 | 0.050 |
Why?
|
| Hematoma | 1 | 2023 | 80 | 0.050 |
Why?
|
| Radial Artery | 1 | 2023 | 54 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2023 | 124 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 131 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2022 | 126 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2022 | 71 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 44 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2022 | 68 | 0.040 |
Why?
|
| New Mexico | 1 | 2021 | 9 | 0.040 |
Why?
|
| Arizona | 1 | 2021 | 14 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 39 | 0.040 |
Why?
|
| Texas | 1 | 2021 | 57 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2022 | 103 | 0.040 |
Why?
|
| Endocardium | 1 | 2021 | 13 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 358 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 173 | 0.040 |
Why?
|
| Troponin I | 1 | 2021 | 35 | 0.040 |
Why?
|
| California | 1 | 2021 | 175 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 55 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 885 | 0.040 |
Why?
|
| Niacinamide | 1 | 2020 | 32 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 251 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 258 | 0.040 |
Why?
|
| Incidence | 1 | 2024 | 1383 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 329 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 176 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 321 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 587 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 455 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 447 | 0.040 |
Why?
|
| Echocardiography | 1 | 2022 | 509 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 288 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 381 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1019 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 455 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2021 | 554 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 872 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 575 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 2018 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1431 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1162 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2012 | 106 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 35 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 174 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1130 | 0.020 |
Why?
|